Cargando…
Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
BACKGROUND: The Step trial raised the possibility that uncircumcised men with pre-existing Ad5 neutralizing antibodies carried an increased risk of HIV infection after vaccination. Thus, understanding Ad seropositivity in humans is important to the development of an AIDS vaccine. Here, we analyze th...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319553/ https://www.ncbi.nlm.nih.gov/pubmed/22496775 http://dx.doi.org/10.1371/journal.pone.0033969 |
_version_ | 1782228728140529664 |
---|---|
author | Cheng, Cheng Wang, LingShu Gall, Jason G. D. Nason, Martha Schwartz, Richard M. McElrath, M. Juliana DeRosa, Steven C. Hural, John Corey, Lawrence Buchbinder, Susan P. Nabel, Gary J. |
author_facet | Cheng, Cheng Wang, LingShu Gall, Jason G. D. Nason, Martha Schwartz, Richard M. McElrath, M. Juliana DeRosa, Steven C. Hural, John Corey, Lawrence Buchbinder, Susan P. Nabel, Gary J. |
author_sort | Cheng, Cheng |
collection | PubMed |
description | BACKGROUND: The Step trial raised the possibility that uncircumcised men with pre-existing Ad5 neutralizing antibodies carried an increased risk of HIV infection after vaccination. Thus, understanding Ad seropositivity in humans is important to the development of an AIDS vaccine. Here, we analyze the impact of different Ad5-specific neutralizing antibodies on immune function and clinical outcome. METHODS AND FINDINGS: Ad seropositivity in the Step trial volunteers was analyzed using chimeric rAd5/35 vectors to characterize their specificity for Ad5 fiber and non-fiber external (capsid) proteins. Immune responses and HIV seropositivity were correlated with the specificity of Ad5-neutralizing antibodies. Neutralizing antibodies induced by the vaccine in Ad5 seronegative subjects were directed preferentially to Ad5 capsid proteins, although some fiber-neutralizing antibodies could be detected. Pre-vaccination Ad5 serostatus did not affect the capsid-directed response after three vaccinations. In contrast, anti-fiber antibody titers were significantly higher in volunteers who were Ad5 seropositive prior to vaccination. Those Ad5 seropositive subjects who generated anti-capsid responses showed a marked reduction in vaccine-induced CD8 responses. Unexpectedly, anti-vector immunity differed qualitatively in Ad5 seropositive participants who became HIV-1 infected compared to uninfected case controls; Ad5 seropositive participants who later acquired HIV had lower neutralizing antibodies to capsid. Moreover, Ad35 seropositivity was decreased in HIV-infected subjects compared with uninfected case controls, while seroprevalence for other serotypes including Ad14, Ad28 and Ad41 was similar in both groups. CONCLUSIONS: Together, these findings suggest that the case subjects were less immunologically responsive prior to infection. Subjects infected during the Step trial had qualitative differences in immunity that increased their risk of HIV-1 infection independent of vaccination. |
format | Online Article Text |
id | pubmed-3319553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33195532012-04-11 Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination Cheng, Cheng Wang, LingShu Gall, Jason G. D. Nason, Martha Schwartz, Richard M. McElrath, M. Juliana DeRosa, Steven C. Hural, John Corey, Lawrence Buchbinder, Susan P. Nabel, Gary J. PLoS One Research Article BACKGROUND: The Step trial raised the possibility that uncircumcised men with pre-existing Ad5 neutralizing antibodies carried an increased risk of HIV infection after vaccination. Thus, understanding Ad seropositivity in humans is important to the development of an AIDS vaccine. Here, we analyze the impact of different Ad5-specific neutralizing antibodies on immune function and clinical outcome. METHODS AND FINDINGS: Ad seropositivity in the Step trial volunteers was analyzed using chimeric rAd5/35 vectors to characterize their specificity for Ad5 fiber and non-fiber external (capsid) proteins. Immune responses and HIV seropositivity were correlated with the specificity of Ad5-neutralizing antibodies. Neutralizing antibodies induced by the vaccine in Ad5 seronegative subjects were directed preferentially to Ad5 capsid proteins, although some fiber-neutralizing antibodies could be detected. Pre-vaccination Ad5 serostatus did not affect the capsid-directed response after three vaccinations. In contrast, anti-fiber antibody titers were significantly higher in volunteers who were Ad5 seropositive prior to vaccination. Those Ad5 seropositive subjects who generated anti-capsid responses showed a marked reduction in vaccine-induced CD8 responses. Unexpectedly, anti-vector immunity differed qualitatively in Ad5 seropositive participants who became HIV-1 infected compared to uninfected case controls; Ad5 seropositive participants who later acquired HIV had lower neutralizing antibodies to capsid. Moreover, Ad35 seropositivity was decreased in HIV-infected subjects compared with uninfected case controls, while seroprevalence for other serotypes including Ad14, Ad28 and Ad41 was similar in both groups. CONCLUSIONS: Together, these findings suggest that the case subjects were less immunologically responsive prior to infection. Subjects infected during the Step trial had qualitative differences in immunity that increased their risk of HIV-1 infection independent of vaccination. Public Library of Science 2012-04-04 /pmc/articles/PMC3319553/ /pubmed/22496775 http://dx.doi.org/10.1371/journal.pone.0033969 Text en This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Cheng, Cheng Wang, LingShu Gall, Jason G. D. Nason, Martha Schwartz, Richard M. McElrath, M. Juliana DeRosa, Steven C. Hural, John Corey, Lawrence Buchbinder, Susan P. Nabel, Gary J. Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination |
title | Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination |
title_full | Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination |
title_fullStr | Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination |
title_full_unstemmed | Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination |
title_short | Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination |
title_sort | decreased pre-existing ad5 capsid and ad35 neutralizing antibodies increase hiv-1 infection risk in the step trial independent of vaccination |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319553/ https://www.ncbi.nlm.nih.gov/pubmed/22496775 http://dx.doi.org/10.1371/journal.pone.0033969 |
work_keys_str_mv | AT chengcheng decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT wanglingshu decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT galljasongd decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT nasonmartha decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT schwartzrichardm decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT mcelrathmjuliana decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT derosastevenc decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT huraljohn decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT coreylawrence decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT buchbindersusanp decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination AT nabelgaryj decreasedpreexistingad5capsidandad35neutralizingantibodiesincreasehiv1infectionriskinthesteptrialindependentofvaccination |